Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: a systematic review

Sherry G. Mansour, Jeremy Puthumana, Steven G. Coca, Mark Gentry, Chirag Parikh

Research output: Contribution to journalArticle

Abstract

Background: Fibrosis is the unifying pathway leading to chronic kidney disease. Identifying biomarkers of fibrosis may help predict disease progression. Methods: We performed a systematic review to evaluate the reliability of blood and urine biomarkers in identifying fibrosis on biopsy as well as predicting renal outcomes. Using MEDLINE and EMBASE, a two-stage search strategy was implemented. Stage I identified a library of biomarkers correlating with fibrosis on biopsy. Stage II evaluated the association between biomarkers identified in stage I, and renal outcomes. Only biomarkers with moderate positive correlation with fibrosis (r > 0.40) or acceptable area under the curve (AUC >0.65) advanced to stage II. Results: Stage I identified 17 studies and 14 biomarkers. Five biomarkers met criteria to advance to stage II, but only three were independently associated with renal outcomes. Transforming growth factor β (TGF-β) correlated with fibrosis (r = 0.60), and was associated with 1.7-3.9 times the risk of worsening renal function in 426 patients. Monocyte chemoattractant protein-1 (MCP-1) diagnosed fibrosis with AUC of 0.66 and was associated with 2.3-11.0 times the risk of worsening renal function in 596 patients. Matrix metalloproteinase-2 (MMP-2) correlated with fibrosis (r = 0.41), and was associated with 2.5 times the risk of worsening renal function. Conclusions: Given the heterogeneity of the data due to diverse patient populations along with differing renal outcomes, a meta-analysis could not be conducted. Nonetheless we can conclude from the published data that TGF-β, MCP-1 and MMP-2 may identify patients at risk for renal fibrosis and hence worse renal outcomes.

Original languageEnglish (US)
Article number72
JournalBMC Nephrology
Volume18
Issue number1
DOIs
StatePublished - Feb 20 2017

Fingerprint

Fibrosis
Biomarkers
Kidney
Area Under Curve
Chemokine CCL2
Matrix Metalloproteinase 2
Transforming Growth Factors
Biopsy
Chronic Renal Insufficiency
MEDLINE
Disease Progression
Meta-Analysis
Urine
Population

Keywords

  • Biomarkers
  • Chronic kidney disease
  • Fibrosis
  • Outcomes
  • Renal biopsy
  • Renal disease progression

ASJC Scopus subject areas

  • Nephrology

Cite this

Biomarkers for the detection of renal fibrosis and prediction of renal outcomes : a systematic review. / Mansour, Sherry G.; Puthumana, Jeremy; Coca, Steven G.; Gentry, Mark; Parikh, Chirag.

In: BMC Nephrology, Vol. 18, No. 1, 72, 20.02.2017.

Research output: Contribution to journalArticle

Mansour, Sherry G. ; Puthumana, Jeremy ; Coca, Steven G. ; Gentry, Mark ; Parikh, Chirag. / Biomarkers for the detection of renal fibrosis and prediction of renal outcomes : a systematic review. In: BMC Nephrology. 2017 ; Vol. 18, No. 1.
@article{358648bc016d449b91ad4dfc2028b5da,
title = "Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: a systematic review",
abstract = "Background: Fibrosis is the unifying pathway leading to chronic kidney disease. Identifying biomarkers of fibrosis may help predict disease progression. Methods: We performed a systematic review to evaluate the reliability of blood and urine biomarkers in identifying fibrosis on biopsy as well as predicting renal outcomes. Using MEDLINE and EMBASE, a two-stage search strategy was implemented. Stage I identified a library of biomarkers correlating with fibrosis on biopsy. Stage II evaluated the association between biomarkers identified in stage I, and renal outcomes. Only biomarkers with moderate positive correlation with fibrosis (r > 0.40) or acceptable area under the curve (AUC >0.65) advanced to stage II. Results: Stage I identified 17 studies and 14 biomarkers. Five biomarkers met criteria to advance to stage II, but only three were independently associated with renal outcomes. Transforming growth factor β (TGF-β) correlated with fibrosis (r = 0.60), and was associated with 1.7-3.9 times the risk of worsening renal function in 426 patients. Monocyte chemoattractant protein-1 (MCP-1) diagnosed fibrosis with AUC of 0.66 and was associated with 2.3-11.0 times the risk of worsening renal function in 596 patients. Matrix metalloproteinase-2 (MMP-2) correlated with fibrosis (r = 0.41), and was associated with 2.5 times the risk of worsening renal function. Conclusions: Given the heterogeneity of the data due to diverse patient populations along with differing renal outcomes, a meta-analysis could not be conducted. Nonetheless we can conclude from the published data that TGF-β, MCP-1 and MMP-2 may identify patients at risk for renal fibrosis and hence worse renal outcomes.",
keywords = "Biomarkers, Chronic kidney disease, Fibrosis, Outcomes, Renal biopsy, Renal disease progression",
author = "Mansour, {Sherry G.} and Jeremy Puthumana and Coca, {Steven G.} and Mark Gentry and Chirag Parikh",
year = "2017",
month = "2",
day = "20",
doi = "10.1186/s12882-017-0490-0",
language = "English (US)",
volume = "18",
journal = "BMC Nephrology",
issn = "1471-2369",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Biomarkers for the detection of renal fibrosis and prediction of renal outcomes

T2 - a systematic review

AU - Mansour, Sherry G.

AU - Puthumana, Jeremy

AU - Coca, Steven G.

AU - Gentry, Mark

AU - Parikh, Chirag

PY - 2017/2/20

Y1 - 2017/2/20

N2 - Background: Fibrosis is the unifying pathway leading to chronic kidney disease. Identifying biomarkers of fibrosis may help predict disease progression. Methods: We performed a systematic review to evaluate the reliability of blood and urine biomarkers in identifying fibrosis on biopsy as well as predicting renal outcomes. Using MEDLINE and EMBASE, a two-stage search strategy was implemented. Stage I identified a library of biomarkers correlating with fibrosis on biopsy. Stage II evaluated the association between biomarkers identified in stage I, and renal outcomes. Only biomarkers with moderate positive correlation with fibrosis (r > 0.40) or acceptable area under the curve (AUC >0.65) advanced to stage II. Results: Stage I identified 17 studies and 14 biomarkers. Five biomarkers met criteria to advance to stage II, but only three were independently associated with renal outcomes. Transforming growth factor β (TGF-β) correlated with fibrosis (r = 0.60), and was associated with 1.7-3.9 times the risk of worsening renal function in 426 patients. Monocyte chemoattractant protein-1 (MCP-1) diagnosed fibrosis with AUC of 0.66 and was associated with 2.3-11.0 times the risk of worsening renal function in 596 patients. Matrix metalloproteinase-2 (MMP-2) correlated with fibrosis (r = 0.41), and was associated with 2.5 times the risk of worsening renal function. Conclusions: Given the heterogeneity of the data due to diverse patient populations along with differing renal outcomes, a meta-analysis could not be conducted. Nonetheless we can conclude from the published data that TGF-β, MCP-1 and MMP-2 may identify patients at risk for renal fibrosis and hence worse renal outcomes.

AB - Background: Fibrosis is the unifying pathway leading to chronic kidney disease. Identifying biomarkers of fibrosis may help predict disease progression. Methods: We performed a systematic review to evaluate the reliability of blood and urine biomarkers in identifying fibrosis on biopsy as well as predicting renal outcomes. Using MEDLINE and EMBASE, a two-stage search strategy was implemented. Stage I identified a library of biomarkers correlating with fibrosis on biopsy. Stage II evaluated the association between biomarkers identified in stage I, and renal outcomes. Only biomarkers with moderate positive correlation with fibrosis (r > 0.40) or acceptable area under the curve (AUC >0.65) advanced to stage II. Results: Stage I identified 17 studies and 14 biomarkers. Five biomarkers met criteria to advance to stage II, but only three were independently associated with renal outcomes. Transforming growth factor β (TGF-β) correlated with fibrosis (r = 0.60), and was associated with 1.7-3.9 times the risk of worsening renal function in 426 patients. Monocyte chemoattractant protein-1 (MCP-1) diagnosed fibrosis with AUC of 0.66 and was associated with 2.3-11.0 times the risk of worsening renal function in 596 patients. Matrix metalloproteinase-2 (MMP-2) correlated with fibrosis (r = 0.41), and was associated with 2.5 times the risk of worsening renal function. Conclusions: Given the heterogeneity of the data due to diverse patient populations along with differing renal outcomes, a meta-analysis could not be conducted. Nonetheless we can conclude from the published data that TGF-β, MCP-1 and MMP-2 may identify patients at risk for renal fibrosis and hence worse renal outcomes.

KW - Biomarkers

KW - Chronic kidney disease

KW - Fibrosis

KW - Outcomes

KW - Renal biopsy

KW - Renal disease progression

UR - http://www.scopus.com/inward/record.url?scp=85013481337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013481337&partnerID=8YFLogxK

U2 - 10.1186/s12882-017-0490-0

DO - 10.1186/s12882-017-0490-0

M3 - Article

C2 - 28219345

AN - SCOPUS:85013481337

VL - 18

JO - BMC Nephrology

JF - BMC Nephrology

SN - 1471-2369

IS - 1

M1 - 72

ER -